FDA Approves LIBTAYO® in Combination with Chemotherapy for Non-Small Cell Lung Cancer
TAFINLAR® and MEKINIST® versus OPDIVO® plus YERVOY® for Patients with Advanced BRAF-Mutant Melanoma: The DREAMseq Trial
Association of Gut Microbiome with Immune Checkpoint Inhibitor Response in Advanced Melanoma
NUBEQA® Combination Improves Overall Survival in Metastatic Hormone Sensitive Prostate Cancer
XPOVIO® (selinexor): A Treatment Approved for Multiple Myeloma as Early as First Relapse
BRUKINSA® Superior to IMBRUVICA® in Relapsed/Refractory CLL/SLL
RNF43 Mutations Predict Response to Anti-BRAF/EGFR Combination Therapy in BRAF V600E Metastatic Colorectal Cancer
FDA Approves TECVAYLI® for Relapsed or Refractory Multiple Myeloma
FDA Approves IMJUDO® plus IMFINZI® for Patients with Advanced Hepatocellular Carcinoma
Improved Outcomes with Early Switch to Fulvestrant Plus Palbociclib in ESR1 Mutated Advanced Breast Cancer
Elevated White Cell Count and Risk of Thrombotic Events in Polycythemia Vera
Association Between Polycystic Ovary Syndrome and Risk of Pancreatic Cancer
Lung Cancer Screening with Low Dose CT Associated with Favorable Stage Shift and Improved Survival
OPDIVO® (nivolumab) for the Adjuvant Treatment of High-Risk Urothelial Carcinoma*
FDA Grants Accelerated Approval to LYTGOBI® for Cholangiocarcinoma
Expansion of Cancer Risk Profile beyond Breast and Ovarian Cancer for BRCA1 and BRCA2 Pathogenic Variants
FDA Grants Tumor-Agnostic Accelerated Approval to RETEVMO®
Avoiding Radioiodine Therapy following Thyroidectomy in Patients with Low-Risk Thyroid Cancer
Late Breaking Abstract – ESMO 2022: PADCEV® plus KEYTRUDA® in Previously Untreated Cisplatin-Ineligible Patients with Locally Advanced or Metastatic Urothelial Cancer
Late Breaking Abstract – ESMO 2022: Neoadjuvant KEYTRUDA® with Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma
Bottom Ad
Advertisement
Subscribe
